Overview

This trial is active, not recruiting.

Condition pancreatic cancer
Treatments cart-meso-19 t cells, cyclophosphamide
Phase phase 1
Sponsor University of Pennsylvania
Collaborator University of California, San Francisco
Start date May 2015
End date September 2017
Trial size 12 participants
Trial identifier NCT02465983, CART-meso-19, UCSF CC144520, UPCC 19214

Summary

This is a study in which pancreatic cancer patients receive a combination therapy with CART-meso cells and CART19 cells administered at 3 days after one dose of cyclophosphamide. CART-meso cells are patients' own T cells that were modified in the laboratory to express a receptor specific to the mesothelin protein. CART19 cells are patients' own T cells that were modified in the laboratory to express a receptor specific to a protein called CD19. The CD19 protein is expressed on white blood B cells. CART19 cells are expected to attack the B cells and impede the antibody response against CART-meso cells. The investigators hypothesize that this combination therapy may prolong the duration of CART-meso cells in the body. Additionally, one dose of cyclophosphamide may enhance engraftment and persistence of CART cells.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
A single dose of CART-meso-19 T cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting.
cart-meso-19 t cells
A single dose of CART-meso-19 cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting. Patients will receive CART cell treatment on an outpatient basis.
cyclophosphamide
A single dose of chemotherapy to be administered prior to dosing of the CART-meso-19 cells

Primary Outcomes

Measure
Safety of IV administration of CART-meso-19 with cyclophosphamide as lymphodepleting chemotherapy in patients with pancreatic cancer using the NCI CTCAE v4.03 criteria
time frame: 24 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Signed informed consent - Unresectable or metastatic pancreatic cancer - Persistent cancer after at least one prior standard of care chemotherapy for advanced stage disease - 18 years of age and older - ECOG performance status of 0 or 1 - Life expectancy greater than 3 months - Satisfactory organ and bone marrow function - Meets blood coagulation parameters - Male and Female subjects of reproductive potential agree to use approved contraceptive methods Exclusion Criteria: - Participation in a therapeutic investigational study within 4 weeks prior to the screening visit - Anticipated need for systemic chemotherapy within 2 weeks before apheresis and infusion - Active invasive cancer other than pancreatic cancer - HIV, HCV, or HBV infections - Active autoimmune disease requiring immunosuppressive therapy within 4 weeks prior to screening visit, with exception of thyroid replacement - Ongoing or active infection - Planned concurrent treatment with systemic high dose corticosteroids - Patients requiring supplemental oxygen therapy - Prior therapy with gene modified cells - Previous experimental therapy with SS1 moiety, murine or chimeric antibodies - History of allergy to murine proteins - History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40) - Clinically significant pericardial effusion, CHF, or cardiovascular condition that would preclude assessment of mesothelin induced pericarditis or that may worsen as a result of toxicities expected for this study - Pregnant or breastfeeding women

Additional Information

Official title Pilot Study of Autologous T-cells Redirected to Mesothelin and CD19 With a Chimeric Antigen Receptor in Patients With Metastatic Pancreatic Cancer
Principal investigator Andrew Ko
Description Immunotherapy is a novel and promising approach for the treatment of solid tumors; immunotherapy with chimeric antigen receptor (CAR) T cells (CART cells) in particular has the potential advantage of targeted therapies that can invoke a rapid tumor response, and the advantage of long-lived responses that are the hallmark of engagement of the adaptive immune system such as memory T cells. This is a single arm, open-label, phase I study to determine the safety and feasibility of combination CART-meso cells (autologous T cells lentivirally transduced to express anti-mesothelin scFv fused to TCRζ and 4-1BB costimulatory domains) and CART19 cells (autologous T cells lentivirally transduced to express a humanized anti-CD19 scFv fused to TCRζ and 4-1BB costimulatory domains) in patients with pancreatic cancer following lymphodepletion with cyclophosphamide.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by University of Pennsylvania.